Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
Mikhail Binnewies(University of California, San Francisco), Matthew F. Krummel(University of California, San Francisco), Kevin C. Barry(Fred Hutch Cancer Center), Megan K. Ruhland(Oregon Health & Science University), Kelly Kersten(University of California, San Francisco), Adil Daud(University of California, San Francisco), Marwan Abushawish, Adriana M. Mujal(Memorial Sloan Kettering Cancer Center), Edward W. Roberts(University of Glasgow), Marko Spasić(University of California, San Francisco), Jessica Tsui(University of California, San Francisco), Jonathan P. Giurintano(University of California, San Francisco), Patrick K. Ha(University of California, San Francisco), Alexis J. Combes(University of California, San Francisco), Joshua L. Pollack, Emily A. Hardison(University of California, San Francisco), Vincent Chan(University of California, San Francisco), Chun Ye(Universidad Católica de Santa Fe)
Cited by 617
Related Papers
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
|Nature Medicine|2018|1k
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
|Immunity|2018|937
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
|Journal of Clinical Oncology|2016|674
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
|Journal of Clinical Oncology|2009|545
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
|Journal of Clinical Investigation|2016|526